Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis

Next Previous
Trial Profile

Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 29 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 13 Oct 2023 Results assessing the occurrence of wearing-off symptoms after (further) extending natalizumab treatment intervals and any changes in frequency, onset, and severity of wearing-offsymptoms over time, presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis.
  • 13 Oct 2023 Protocol of study has been amended for personalized EID starting from 6 weeks with an aim trough concentration of 5 µg/mL for all study participants.
  • 13 Oct 2023 Results analyzing efficacy of personalized EID of natalizumab by therapeutic drug monitoring, presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top